玻璃体腔注射ranibizumab治疗特发性脉络膜新生血管疗效观察  

Intravitreal ranibizumab for treatment of idiopathic choroidal neovascularization： results of a 6-month retrospective trial

作　　者：梁超群[1] 陈长征[1] 易佐慧子[1] 曹思[1] 戚沆[1] 余岚[1] 

机构地区：[1]武汉大学人民医院眼科中心,430060

出　　处：《中国实用眼科杂志》2015年第5期498-501,共4页Chinese Journal of Practical Ophthalmology

摘　　要：目的观察玻璃体腔注射抗血管内皮生长因子单克隆抗体ranibizumab（商品名：Lucen．tis）治疗特发性脉络膜新生血管（ICNV）的近期临床疗效。方法回顾性无对照研究。将2011年8月至2014年1月，在武汉大学人民医院眼科中心就诊的ICNV患者15例15只眼纳入研究。测量最佳矫正视力（BCVA），行眼压、检眼镜、眼底照相、荧光素眼底血管造影（FFA）及光相干断层扫描（OCT）检查。视力转化为标准化logMAR视力进行计算。治疗前平均BCVA为（0．72±0．51）logMAR；黄斑中心凹视网膜厚度（CMT）202～437μm，平均（309．60±59．58）μm。所有患眼玻璃体腔注射10mg／mlranibizumab0．05ml（含ranibizumab0．5mg）。治疗后第1、2、3、6个月各随访1次，对比分析治疗前后BCVA及CMT变化情况。结果末次随访时，所有患眼平均玻璃体腔注射（1．80±1．01）次，矫正视力较治疗前提高（0．37±0．55）logMAR，差异有统计学意义（t=2．611，P〈0．05）；CMT降低（76．80±58．73）μm，差异有统计意义（t=5．065，P〈0．05）。随访期间未发现与治疗相关的全身及眼部并发症。结论玻璃体腔注射ranibizumab治疗特发性脉络膜新生血管视力预后较好，病灶水肿消退明显，安全性高。Objective To observe the safety and efficacy of intravitreal injection of ranibizumab for the treatment of idiopathic choroidal neovascularization （ICNV）. Methods Fifteen patients with ICNV were included in this retrospective, uncontrolled clinical trial. Their eyes were treated with a single intravitreal injection of 0.5 mg ranibizumab at the first time, and then followed by dosing as needed （pro re nata [PRN]） at every follow-up visit at month 1, 2, 3, 6. The inspection findings of best-corrected visual acuity （BCVA）, intraocular pressure, ophthalmoscope, fiandus photography, fun- dus fluorescein angiography （FFA） and optical coherence tomography （OCT） before treatment and at every follow-up visit were observed and analyzed. The average BCVA was （0.72±0.51） log MAR in the baseline; the central macular thickness （CMT） was 202-437μm, the average value was （309.60± 59.58）μm. The changes of BCVA, CMT before and after treatment were observed. Results At the last follow-up, the mean intravitreal injection of ranibizumab of all the eyes was （1.80±1.01） times, the BCVA improved （0.37±0.55） log MAR, the difference was statistically significant （t =2.611, P 〈 0.05）; CMT decreased （76.80±58.73）μm, the difference was statistically significant （t =5.065, P 〈 0.05）. No ocular or systemic adverse events were found after intravitreal injection of ranibizumab during the follow-up duration. Conclusions Intravitreal injection of ranibizumab, which can improvethe visual acuity, reduce the macular edema, showed a promising efficacy and safety profile in the treatment of ICNV.

关 键 词：特发性脉络膜新生血管 抗体 单克隆/治疗应用 RANIBIZUMAB 

分 类 号：R988.1[医药卫生—药品]